<p>Drs. Peter and Takako Jones discuss the ACE-083 trial and the basis of myostatin inhibition for FSHD, and go through the data showing that berberine, despite proof-of-concept studies showing it to be an inhibitor of DUX4 expression, is highly unlikely to be an effective treatment for FSHD.</p>

--- 

Send in a voice message: https://podcasters.spotify.com/pod/show/peter-l-jones/message

What's going on in FSHD, week ending April 30, 2022

MyFSHD is about education and personal empowerment for the worldwide facioscapulohumeral muscular dystrophy (FSHD) community. Here we have discussions and commentary hosted by FSHD researcher Peter Jones, PhD, on many things of interest to the FSHD community. Learn about the science behind the different FSHD therapeutic approaches, FSHD pathology, family genetics and FSHD diagnostics. We will discuss upcoming clinical trials and what to look forward to. You will get to understand how you can be better prepared, become involved, and help contribute to defeating FSHD once and for all.

Anchor (from Spotify)

MyFSHD

What's going on in FSHD, week ending April 23, 2022.

We investigate and help you understand the science behind myostatin inhibition (ACE-083 trial) and berberine supplementation for FSHD; effective in the lab, not so much in you.